The plasma copper protein ceruloplasmin (CP) was found to inhibit endothelial nitric-oxide synthase activation in cultured endothelial cells, in line with previous evidence showing that the endothelium-dependent vasorelaxation of the aorta is impaired by physiological concentrations of ceruloplasmin. The data presented here indicate a direct relationship between the extent of inhibition of agonist-triggered endothelial nitric oxide synthase activation and CP-induced enrichment of the copper content of endothelial cells. Copper discharged by CP was mainly localized in the soluble fraction of cells. The subcellular distribution of the metal seems to be of relevance to the inhibitory effect of CP, because it was mimicked by copper chelates, like copper-histidine, able to selectively enrich the cytosolic fraction of cells, but not by copper salts, which preferentially located the metal to the particulate fraction.
Ceruloplasmin (CP)1 is a copper-containing glycoprotein that is found in the plasma of all vertebrates, in which it carries approximately 90% of plasma copper (1). Each CP molecule tightly binds six copper atoms to the three different copper binding sites that characterize blue oxidases (2, 3). Nevertheless, as indicated by considerable experimental evidence, it is particularly prone to transfer its copper atoms to tissues (4 -6) delivering copper to intracellular copper proteins (7,8). However, recent studies on aceruloplasminemic patients (9 -11) indicate that this protein has no essential role in copper transport, whereas it plays a primary role in iron homeostasis, possibly through its ferroxidase activity (12).Ceruloplasmin is an acute-phase reactant; its concentration in the plasma increases up to 3-fold during pregnancy and during multiple pathological processes including trauma and inflammation (13). Recent attention has focused on the role that this protein may have in the function of the vascular system in health and disease. CP has been detected in human atherosclerotic lesions (14, 15), and it has been shown to oxidize low density lipoproteins in the presence of vascular cells (16). A copper binding site labile to Chelex treatment has been proposed to be responsible for the oxidative damage to low density lipoproteins (17). On the other hand, we have shown that CP, at physiological concentrations, inhibits the endothelium-dependent relaxation of rabbit aorta induced by agonists and that this effect is not due to a trapping of NO by the copper sites (18).Vasodilation requires a (NO)-cGMP transduction pathway between endothelium and smooth muscle cells (19,20). Endothelial NO synthase (eNOS) is a constitutive enzyme that converts L-arginine into NO and citrulline (21) with a relatively low basal activity (22, 23). After agonist stimulation evoking an increase in the [Ca 2ϩ ] i concentration, Ca 2ϩ -bound calmodulin disrupts the inhibitory eNOS-caveolin-1 interactions (24, 25), thereby allowing conformational changes within eNOS, leading to the activated form that produces NO (26,27). The ago...